About Abzu
Abzu is a company based in Copenhagen (Denmark) founded in 2018 by Marco Somma. Abzu has raised $2.16 million across 4 funding rounds from investors including EIC Fund, PreSeed Ventures and Nordic Ventures. Abzu offers products and services including QLattice® and RNA Drug Design Process. Abzu operates in a competitive market with competitors including Owkin, Formation Bio, AbSci, BigHat and Predictive Oncology, among others.
- Headquarter Copenhagen, Denmark
- Founders Marco Somma
- Stage Minicorn
-
Sectors
TechnologyHealthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Abzu Aps
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$2.16 M (USD)
in 4 rounds
-
Latest Funding Round
$2.43 M (USD), Grant
Oct 15, 2022
-
Investors
EIC Fund
& 4 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Abzu
Abzu offers a comprehensive portfolio of products and services, including QLattice® and RNA Drug Design Process.
Explainable AI tool for predictive modeling in drug design.
AI-guided method for creating RNA therapeutics compounds.
People of Abzu
Unlock access to complete
Funding Insights of Abzu
Abzu has successfully raised a total of $2.16M across 4 strategic funding rounds. The most recent funding activity was a Grant round of $2.43 million completed in October 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Abzu
Abzu has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include EIC Fund, PreSeed Ventures and Nordic Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government agency and accelerator focusing on innovative startups and SMEs
|
Locked | Locked | Locked | |
|
Investments in early-stage tech startups are made by Inventure.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Abzu
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Abzu
Investment portfolio details for Abzu
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Abzu
Detailed financials for Abzu
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Abzu Comparisons
Peer comparison for Abzu
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Abzu
Abzu operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Owkin, Formation Bio, AbSci, BigHat and Predictive Oncology, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
An agentic AI platform is developed for biomedical research insights.
|
|
| Locked | Locked | Locked |
AI-powered drug discovery platform for various diseases
|
|
| Locked | Locked | Locked |
AI-based technology is used for recombinant protein production in therapeutics.
|
|
| Locked | Locked | Locked |
Antibody therapies are developed through machine learning and synthetic biology.
|
|
| Locked | Locked | Locked |
AI-based platform for cancer diagnostics and precision medicine is utilized.
|
|
| Locked | Locked | Locked |
AI platform used for extracting antibody data from scientific papers.
|
Detailed competitors of Abzu
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Abzu
Complete news archive for Abzu
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Abzu
Abzu was founded in 2018.
Abzu is headquartered in Copenhagen, Denmark.
Casper Wilstrup is the current CEO of Abzu.
Abzu is a funded company, having raised a total of $2.16M across 4 funding rounds to date.
Abzu was founded in 2018 in Copenhagen, Denmark, and operates in the artificial intelligence sector. Machine learning solutions grounded in quantum mechanics and neural networks are developed by the company. Transparent and trustworthy AI systems are offered, with a focus on simulating self-organizing systems to address limitations in traditional approaches. Core activities include advancing AI through these foundational principles, led by co-founders Marco Somma and CEO Casper Wilstrup.
Abzu's top competitors include Owkin, Formation Bio and XtalPi.
Abzu offers QLattice® and RNA Drug Design Process.
Abzu has 5 investors. Key investors include EIC Fund, PreSeed Ventures, Nordic Ventures, Inventure VC, and PSV Deeptech.
The valuation of Abzu is $1.68M as of Sep 2020.